US Patent Issued to Genmab on Oct. 28 for "Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate" (American, Dutch Inventors)

ALEXANDRIA, Va., Oct. 28 -- United States Patent no. 12,453,781, issued on Oct. 28, was assigned to Genmab A/S (Valby, Denmark).

"Methods of treating cancer with a combination of an anti-VEGF antibody and an anti-tissue factor antibody-drug conjugate" was invented by Reshma Abdulla Rangwala (Philadelphia), Sandra Verploegen (Nieuwegein, Netherlands), Esther C. W. Breij (Driebergen, Netherlands), Oyewale O. Abidoye (Bellevue, Wash.) and Leonardo Viana Nicacio (Redmond, Wash.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The invention provides an anti-VEGF antibody (e.g., bevacizumab) in combination with an antibody-drug conjugate that binds to tissue factor (TF) (e.g., tisotumab vedotin) and their use in met...